Tumor Treatment Equipment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

Radiotherapy Equipment is the fastest growing sector, North America is the largest market

The global market for tumor treatment equipment, which includes specialized medical devices like radiotherapy systems and thermal ablation units used for the targeted destruction and management of malignant neoplasms, is projected to expand significantly. Valued at USD 14.23 Billion in 2025, it is expected to reach USD 20.87 Billion by 2031, demonstrating a Compound Annual Growth Rate (CAGR) of 6.59%. This growth is primarily fueled by the increasing global incidence of cancer, which drives the demand for effective therapeutic approaches to enhance patient survival rates.

This rising burden of cancer compels healthcare providers to bolster their treatment capabilities; for instance, the American Cancer Society projected approximately 2,041,910 new cancer cases in the United States for 2025, highlighting a substantial need for advanced oncological care. However, a major impediment to market expansion is the considerable capital investment necessary for procuring and maintaining high-end treatment technologies. These high acquisition and installation costs, along with stringent regulatory compliance, frequently limit the availability of these devices in low-to-middle-income regions and smaller healthcare settings, thus hindering the broad adoption of modern tumor treatment solutions despite the clear clinical demand.

Market Drivers

A key market driver is the integration of Artificial Intelligence (AI) and Machine Learning into treatment planning, which significantly boosts the precision of tumor treatment equipment globally. Advanced algorithms allow clinicians to precisely contour tumors, thereby minimizing radiation exposure to healthy tissues nearby and optimizing dose delivery for intricate cases. This technological advancement not fetches only enhances clinical outcomes but also improves workflow efficiency, leading governments and institutions to invest in these automated systems to manage growing patient numbers.

For example, the UK government announced £82.6 million in funding in February 2025 for projects leveraging AI to diagnose and treat cancer. Simultaneously, increasing healthcare expenditure and infrastructure development are propelling the acquisition of new radiotherapy and ablation systems. Nations are allocating more capital to modernize hospital facilities and procure high-throughput treatment devices to address the rising cancer burden, enabling healthcare providers to replace outdated equipment with compliant linear accelerators and proton therapy units. This financial commitment is reflected in the market, with Siemens Healthineers reporting 3.8% comparable revenue growth in its Advanced Therapies segment in November 2025 due to equipment demand, and Elekta reporting an installed base of over 7,500 devices globally in 2025, showcasing expanding treatment infrastructure.

Market Challenges

A significant challenge for the Global Tumor Treatment Equipment Market is the prohibitive capital investment required for both acquiring and maintaining high-end treatment technologies. The substantial upfront costs associated with these advanced devices frequently surpass the financial capabilities of smaller healthcare facilities and institutions, particularly in low-to-middle-income regions. This economic strain limits the customer base primarily to well-funded urban centers, thereby creating a bottleneck that impedes the widespread adoption of essential therapeutic infrastructure.

Consequently, when healthcare providers cannot secure adequate funding or foresee a viable return on investment, the procurement of these crucial therapeutic units is often delayed or canceled, directly shrinking the total addressable market. This financial burden is compounded by declining operational revenues, making it increasingly difficult for medical centers to recover their capital investments. Uncertainty about long-term profitability compels hospitals to extend the lifespan of obsolete machinery instead of investing in new systems. For instance, in 2025, the American Society for Radiation Oncology noted a net reduction in Medicare reimbursement payments, adding to a cumulative 23% decline over the prior decade. Such fiscal instability directly hinders market growth by curtailing providers' capacity to finance the installation and complex regulatory upkeep of modern cancer treatment equipment.

Market Trends

A pivotal market trend is the expansion of Proton Therapy and Particle Beam Treatment Centers, which reflects a move towards delivering high-precision radiation with minimal exit doses, especially beneficial for pediatric and complex Central Nervous System (CNS) tumors. This trend involves building specialized facilities equipped with cyclotrons to generate charged particles, providing superior dose conformity compared to conventional photon-based systems. Healthcare networks are actively increasing their capacity to offer this treatment as a standard of care, despite the substantial infrastructural requirements.

For example, Penn Medicine broke ground on a new $224 million proton therapy center in April 2025 to enhance system-wide access to advanced particle therapy. Concurrently, the proliferation of Robotic-Assisted Surgical Oncology Platforms is transforming tumor resection by facilitating minimally invasive procedures with improved dexterity and visualization.

These platforms empower surgeons to execute intricate dissections within confined anatomical areas, thereby considerably shortening postoperative recovery times and hospital stays for cancer patients. The market is experiencing a continuous rise in utilization as clinical applications extend beyond urology to encompass thoracic and general surgical oncology. Intuitive Surgical, for instance, reported approximately 20% year-over-year growth in worldwide procedures in October 2025, boosting its global installed base to 10,763 robotic systems.

Key Market Players

• Boston Scientific Corp
• Medtronic plc.
• Johnson & Johnson
• Merit Medical Inc.
• Varian Medical Inc.
• AngioDynamics Inc.
• HealthTronics Inc.
• SonaCare Medical LLC
• Misonix Inc.
• CAScination AG

Report Scope

In this report, the Global Tumor Treatment Equipment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Tumor Treatment Equipment Market, by Type:

• Surgical Equipment
• Radiotherapy Equipment
• Chemotherapy Equipment

Tumor Treatment Equipment Market, by Application:

• Lung Cancer
• Rectal Cancer
• Breast Cancer
• Other

Tumor Treatment Equipment Market, by Region:

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Tumor Treatment Equipment Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.